Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

Hyejin Choi, Jiehui Deng, Shuai Li, Tarik Silk, Lauren Dong, Elliott J. Brea, Sean Houghton, David Redmond, Hong Zhong, Jonathan Boiarsky, Esra Akbay, Paul D. Smith, Taha Merghoub, Kwok Kin Wong, Jedd D. Wolchok

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

KRAS mutant non-small-cell lung cancer (NSCLC) remains refractory to targeted therapeutics. Choi et al. show that pulsatile, rather than continuous, treatment with MEK inhibitors can maintain T cell activity better and prolong survival in mice with Kras mutant cancer. This effect is further enhanced when combined with CTLA-4 blockade.

Original languageEnglish (US)
Pages (from-to)806-819.e5
JournalCell Reports
Volume27
Issue number3
DOIs
StatePublished - Apr 16 2019

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer'. Together they form a unique fingerprint.

Cite this